Risk of new-onset inflammatory bowel disease among patients with acne vulgaris exposed to isotretinoin - 05/12/20
Abstract |
Background |
Data on the risk of inflammatory bowel disease (IBD) among isotretinoin-exposed patients with acne vulgaris (AV) is controversial.
Objective |
To compare IBD risk in isotretinoin-exposed and unexposed patients with AV.
Methods |
Retrospective cohort analysis of patients with AV with and without isotretinoin exposure identified using electronic health records. Primary outcomes were 6-month and 1-year IBD incidence.
Results |
The crude 6-month IBD incidence was 0.08% (21/27,230) among isotretinoin-exposed patients with AV compared to 0.04% (254/631,089) among those unexposed. The crude 1-year IBD incidence was 0.10% (28/27,230) among isotretinoin exposed patients with AV and 0.08% (477/631,089) among those unexposed. The odds of developing IBD within 6 months were 87% higher among isotretinoin-exposed patients with AV compared to those unexposed (adjusted odds ratio, 1.87; 95% confidence interval [CI], 1.20-2.93), although the absolute difference was small (risk difference, 2.6 more cases per 10,000 patients; 95% CI, 0.7-4.5). There was no significant difference in the odds of developing IBD at 1 year between isotretinoin-exposed and unexposed patients with AV (adjusted odds ratio, 1.40; 95% CI, 0.95-2.05).
Limitations |
Isotretinoin-exposed patients may be more likely to have IBD detected by a health care provider.
Conclusions |
IBD incidence among isotretinoin-exposed patients with AV is very low, and the risk appears similar to that for unexposed patients with AV.
Le texte complet de cet article est disponible en PDF.Key words : acne vulgaris, Explorys, inflammatory bowel disease, isotretinoin, risk
Abbreviations used : AV, CD, CI, IBD, ICD, OR, SNOMED-CT, UC
Plan
| Funding sources: None. |
|
| Disclosure: Dr Garg is an advisor for AbbVie, Amgen, Boehringer Ingelheim, Incyte, Janssen, Novartis, Pfizer, UCB, and Viela Bio and receives research grants from AbbVie and National Psoriasis Foundation. Authors Wright and Strunk have no conflicts of interest to declare. |
|
| IRB approval status: Reviewed and approved by the human subjects committee at the Feinstein Institutes for Medical Research at the Northwell Health. |
|
| Reprints not available from the authors. |
Vol 84 - N° 1
P. 41-45 - janvier 2021 Retour au numéro
Article précédent
- A 20-year histopathologic study of pediatric nevi at an academic institution
- Danna Moustafa, Lyn M. Duncan, Elena B. Hawryluk
- The global, regional, and national burden of psoriasis in 195 countries and territories, 1990 to 2017: A systematic analysis from the Global Burden of Disease Study 2017
- Sino Mehrmal, Prabhdeep Uppal, Natalie Nedley, Rachel L. Giesey, Gregory R. Delost
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?